Unity Biotechnology Inc (NAS:UBX)
$ 0.999 -0.036 (-3.48%) Market Cap: 16.83 Mil Enterprise Value: 9.10 Mil PE Ratio: 0 PB Ratio: 1.19 GF Score: 32/100

UNITY Biotechnology Inc at Cowen Health Care Conference Transcript

Mar 07, 2023 / 02:50PM GMT
Release Date Price: $4.79 (+3.01%)
Unidentified Analyst

Awesome, well, thank you, Anirvan from Unity for being here at the 43rd Annual Cowen Healthcare Conference. So excited to have you here [because we're excited about your story. So thank you for joining us virtually. So I will turn it to you, Anirvan].

Anirvan Ghosh
Unity Biotechnology, Inc. - CEO

Right. Thanks. I'm pleased to provide an update on our lead program, UBX1325 and our upcoming data readouts in the coming months. Before I get started, I just wanted to remind you that I'll be making forward-looking statements during my presentation today that are summarized over here and detailed in our SEC filings.

At Unity, we are developing a new class of therapeutics called senolytics to target progressive vision loss. The two indications are primarily focused on our diabetic macular edema and age-related macular degeneration. These are two major causes of vision loss globally. And despite being one of the standard of care treatment anti-VEGF, many patients do not get to 2040 or otherwise good vision.

We recently shared Phase 2 data

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot